BioFinlandin jäsen

TILT Biotherapeutics is a biotechnology company developing a clinically validated intravenous adenoviral immunotherapy platform. Its patented TILT® technology uses genetically modified viruses designed to selectively target cancer cells and activate the immune system to recognize and destroy solid tumors. By enabling intravenous delivery, the platform allows these therapeutic viruses to circulate throughout the body, potentially reaching both primary and metastatic tumors more effectively. This systemic approach enhances the ability to treat cancers that are difficult to access with localized therapies. The company’s mission is to reshape cancer treatment by advancing innovative investigational therapies that aim to provide new hope for patients with solid tumors who have limited treatment options.